**Name of Journal: *World Journal of Clinical Oncology***

**ESPS Manuscript NO: 24635**

**Manuscript Type: Original Article**

***Retrospective Cohort Study***

**Contralateral prophylactic mastectomy rate stable at major Canadian breast cancer center**

Roberts A *et al*. Contralateral prophylactic mastectomy rate Canada

**Amanda Roberts, Lakhbir Sandhu, Tulin D Cil, Stefan OP Hofer, Toni Zhong**

**Amanda Roberts, Lakhbir Sandhu,** Department of Surgery, University of Toronto, Toronto, ON M5G 2C4, Canada

**Tulin D Cil,** Division of General Surgery, University Health Network and Women’s College Hospital, Toronto, ON M5G 2M9, Canada

**Stefan OP Hofer, Toni Zhong,** Division of Plastic and Reconstructive Surgery, University Health Network, Toronto General Hospital, Toronto, ON M5G 2C4, Canada

**Author contributions:** Roberts A completed the data collection and prepared the manuscript; Sandhu L analyzed the data; Roberts A, Cil TD and Zhong T developed the research question and concept; Sandhu L, Cil TD, Hofer SOP and Zhong T provided feedback on research and critically appraised manuscript.

**Institutional review board statement:** Research Ethics Board approval was acquired from the University Health Network and maintained throughout the study.

**Informed consent statement:** Not applicable.

**Conflict-of-interest statement:** None of the authors declare any conflicts of interest and/or commercial involvement.

**Data sharing statement:** There is no additional data available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Toni Zhong, MD, MHS, FRCSC, Associate Professor,** Division of Plastic and Reconstructive Surgery, University Health Network, Toronto General Hospital, 8N-871, Toronto, ON M5G 2C4, Canada. toni.zhong@uhn.ca

**Telephone:** +1-416-3403858

**Received:** January 30, 2016

**Peer-review started:** January 30, 2016

**First decision:** March 24, 2016

**Revised:** April 16, 2016

**Accepted:** May 7, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To examine trends of contralateral prophylactic mastectomy (CPM) rates at a Canadian academic breast cancer center.

**METHODS:** A single-institution retrospective cohort study was completed. Women of any age who underwent at least a unilateral mastectomy (UM) for primary unilateral breast carcinoma between January 1, 2004 and December 31, 2010 were included. Patients who underwent CPM on the same day as UM were isolated to create two distinct cohorts. Patient and procedure characteristics were compared across groups using R software (version 3.1.0).The percentage of CPMs per year was determined. The Cochrane-Armitage test was used to assess the trend of CPMs over time. A *P* value of < 0.05 was considered significant.

**RESULTS:** A total of 811 women met the inclusions/exclusion criteria; 759 (93.6%) underwent UM alone and 52 (6.4%) underwent UM with immediate CPM. The absolute number of procedures (UM and UM + CPM) increased over time, from 83 in 2004 to 147 in 2010 reflecting an increase in mastectomy volume. Annual CPM rates did not increase over time (*P* = 0.7) and varied between 2.6% to 10.7%. Family history of breast cancer [OR 3.6 (1.8-7.3)] and immediate reconstruction [10.0 (5.2-19.3)] were both significantly associated with CPM. Women who underwent CPM were younger (median age CPM 49 years *vs* UM 52 years, *P* < 0.0001) but age less than 50 years was not statistically associated with increased rates of CPM.

**CONCLUSION:** CPM rates from 2004 to 2010 at a high-volume Canadian breast cancer center did not increase over time, in contrast to trends observed in the United States.

**Key words:** Breast; Oncology; Prophylactic; Mastectomy; Surgery

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Contralateral prophylactic mastectomy rates from 2004 to 2010 at a high-volume Canadian breast cancer center do not demonstrate the same rising trend observed in the United States.

Roberts A, Sandhu L, Cil TD, Hofer SOP, Zhong T. Contralateral prophylactic mastectomy rate stable at major Canadian breast cancer center. *World J Clin Oncol* 2016; In press

**INTRODUCTION**

During the past decade, the percentage of women with unilateral breast carcinomas undergoing immediate contralateral prophylactic mastectomy (CPM) has steadily increased over time[1-3] despite minimal evidence supporting a survival benefit[4-7]. These increased CPM rates have mainly been described in literature from the United States. CPM trends of similar magnitude and scope have not been quantitatively documented in literature from countries outside of the United States. Switzerland and England have reported much lower CPM rates during a similar time period as the United States data[8,9] - with no significant increase over time noted in Switzerland. It is possible that in these countries, as well as in Canada, where the health care system is based on a socialized medicine model, and surgeons routinely practice under budgetary restraints; a nonlife-saving surgical service such as CPM may not be as readily available as in the United States.

In Canada, lower CPM rates have been noted on a national level compared to the United States[10], but these rates were obtained through administrative databases and no patient level, surgical procedure detail, or outcomes data were reported[10]. Since CPM rates are known to be influenced by resource factors, such as access to genetic testing and immediate breast reconstruction, and other patient factors such as age[1-3,7,8,11-14], examining CPM trends with patient and procedure level data will provide more detailed information on the CPM landscape in Canada.

Therefore, our main objective was to examine the rates and trends of immediate CPM and to compare outcomes of patients undergoing CPM to patients having unilateral mastectomy (UM) alone at a Canadian academic breast cancer center.

**MATERIALS AND METHODS**

We conducted a single institution retrospective cohort study using a prospectively maintained database. The Princess Margaret Breast Disease Database contains information on all patients who undergo any form of breast disease evaluation or treatment at the Princess Margaret Hospital in Toronto, Ontario, Canada. There is an opt-out policy for patients who do not wish to have their medical information collected and used for research purposes. Research Ethics Board approval was acquired and maintained throughout the study. The population of interest included women of any age who underwent at least a UM for primary unilateral invasive or in situ breast carcinoma between January 1, 2004 and December 31, 2010. This time period was chosen to be as contemporary as possible while still coinciding with the literature from the United States and Switzerland. Patients who underwent CPM on the same day as the UM were isolated to create two distinct cohorts: women who underwent UM alone and women who underwent UM with immediate CPM. Patients with known bilateral disease at the time of their primary surgery were excluded. A diagnosis of atypical hyperplasia, lobular carcinoma in situ, ductal carcinoma in situ or invasive breast cancer in the contralateral breast was considered as bilateral disease. These exclusions were applied in order to isolate, as accurately as possible, CPMs of truly benign breasts.

Patient and procedure variables were extracted from the database and included: age, history of benign disease, family history of breast cancer, pre-operative BRCA status, pre-operative diagnosis, pre-operative systemic therapy, receipt of radiation, year of surgery, axillary evaluation (sentinel lymph node biopsy or axillary lymph node dissection) and receipt of reconstruction. The incidence of ipsilateral locoregional recurrence and development of a new contralateral breast cancer were also extracted.

Patient and procedure characteristics were compared across groups using R software (version 3.1.0). Mean values and standard deviations were calculated for normally distributed continuous variables and median values with interquartile range (IQR) were calculated for variables with a non-normal distribution. For categorical variables, results were expressed as counts and percentages.The Cochrane-Armitage test was used to assess the trend of CPMs over time. A *P* value of < 0.05 was considered significant. A multivariable logistic regression model was generated with receipt of CPM as the main outcome variable. Covariates used in this model included age, family history of breast cancer, personal history of benign breast disease and receipt of immediate reconstruction. Age was dichotomized to a binary variable (< 50 years or ≥ 50 years old). The remaining covariates were also binary. Covariates were chosen based on clinical significance. Model fit took into consideration any interactions and assessments of collinearity. The statistical review of the study was performed by a biomedical statistician.

**RESULTS**

A total of 811 women met the inclusions/exclusion criteria; 759 (93.6%) underwent UM alone and 52 (6.4%) underwent UM with immediate CPM. The characteristics of each group were summarized in Table 1. The absolute number of procedures (UM and UM + CPM) increased over time, from 83 in 2004 to 147 in 2010 reflecting an increase in mastectomy volume (Figure 1). CPMs per year did not increase over the study time period (*P* = 0.7) and varied between 2.6% to 10.7% (Figure 1).

Women who had a CPM were more likely to be younger [median age CPM = 49 years (range 29-67); UM = 52 years (range 28-88)] and to have a breast cancer family history (CPM 67% *vs* UM 37%, *P* < 0.001). Receipt of neoadjuvant chemotherapy was not significantly different between the two groups (CPM 31% *vs* UM 23%, *P* = 0.23), yet there were significantly more patients in the CPM group who underwent an ALND at the time of mastectomy (CPM 81% *vs* UM 49%, *P* < 0.001). Significantly more patients having CPM underwent immediate reconstruction (CPM 54% *vs* UM 8%, *P* < 0.001).

On the multivariable analysis, CPM patients were almost four times as likely to have a family history of breast cancer compared to those patients who opted for UM alone [OR 3.6, (1.8-7.3) *P* < 0.001]. Patients who had a CPM were also 10 times more likely to receive immediate reconstruction when compared to patients who underwent UM alone [OR 10.0 (5.2-19.3) *P* < 0.001] (Table 2).

Locoregional recurrence rates were no different between the two groups (CPM 4% *vs* UM 3%, *P* = 0.68). Over the same follow-up period, a new contralateral breast cancer was identified in 13 (2.0%) of patients who underwent UM alone. No new contralateral breast cancers were identified in the CPM group, although three (6.0%) of the patients who underwent CPM were found to have incidental invasive disease in the contralateral breast on final pathology.

**DISCUSSION**

Between 2004 and 2010, CPM rates at our single Canadian institution did not show the same increasing trend observed in the United States. During this time period, our CPM rate was 6.4% (range: 2.6% to 10.7%) with no increase over time, while rates in the United States were noted to increase between 2003 and 2010 from 4.1% to 9.7% for all ages, and 9.3% to 24.1% for patients aged 45 years or less[1]. In contrast, during a similar time period in Switzerland, CPM rates remained stable at 7%[8]. In Canada, the only reported data examined national CPM rates between 2007 and 2010 and demonstrated an overall CPM rate of 6% (5% in 2007/2008 to 7% in 2009/2010) - consistent with our institutional results and the rates from Switzerland[8,10].

Interestingly, the factors associated with increased rates of immediate CPM at our institution are similar to those found in the United States literature - suggesting that the patient factors influencing the decision to undergo a CPM are possibly the same between the two countries. Within our population, younger patients and those with family history were more likely to undergo CPM, similar to patients in the numerous United States studies[1-3,7,8,12-14]. Furthermore, the use of immediate reconstruction has been associated with increased CPM rates[11,13], and our study results support this finding.

As noted, the lower CPM rates reported from our single institution are consistent with the national Canadian administrative data yet are considerably lower than those reported in the United States during a similar time period. Despite this lower rate, our data highlight similar patient factors influencing the receipt of CPM. Given these similar patient factors, it may be the health system, or practice environment, of Canadian breast cancer surgeons and patients that is contributing to the discrepancy in CPM rates between Canada and the United States.
 To address the possible influence of the surgeon and their practice environment on mastectomy and CPM rates, Covelli *et al*[15] obtained qualitative data from surgeons in both Canada and the United States in 2012 and 2013. Anecdotally, surgeons in both countries endorsed an increasing CPM rate and highlighted incidental findings on pre-operative MRI, access to reconstruction and the surgeon’s initial discussion of treatment options as possible factors influencing these trends. Differences between the surgeons’ practices were noted mainly by the availability of immediate breast reconstruction - a product of the health system. The majority of United States surgeons had ready access to immediate breast reconstruction whereas this was less commonly available to Canadian breast surgeons[15-17]. Barriers to access immediate breast reconstruction may contribute to more women in Canada seeking out a delayed CPM with bilateral reconstruction years after their initial unilateral therapeutic mastectomy. This model of care has several advantages in our healthcare system, as it obviates any cancer surgery wait-time constraints, delay in adjuvant cancer therapies and allows patients time to seek out an institution where specialized breast reconstruction surgeons are available. In addition to immediate breast reconstruction availability, legislation and guidelines within each country were also felt to influence surgical decisions. Legislation in various United States require the discussion of all treatment options available (including reconstruction) at initial consultation whereas, in Canada, no such legislation exists. This examination at the surgeon level provides evidence that the medico-social context of the patient’s treatment environment, or health system, influences the decision to undergo mastectomy with CPM. These results also lead one to consider if the stable CPM rates in Canada are actually lower overall than in the United States due to these possible practice or health system differences, or if the trends in Canada will eventually mimic those of the United States over time given the surgeons’ anecdotal observations, as a similar “lag” was observed regarding IBR trends in Canada[16,17].

Within our single institution study, we were able to evaluate CPM trends among a large sample of patients undergoing mastectomy for unilateral breast carcinoma at a high-volume academic breast center. The prospectively-collected patient level data provided important information regarding factors that may influence a patient’s decision to undergo a CPM. This patient level data allowed us to not only evaluate the CPM rates, but to also investigate possible influencing factors for CPM and to provide insight on the demographics of CPM patients in Canada.

While our study provides patient level data related to CPM trends, the overall low number of patients who underwent CPM (*n* = 52) should be considered a limitation when interpreting the results as we did not observe a trend over time in regards to CPM rates. While our overall rates are consistent with the national level data, at this point in time it is challenging to draw accurate conclusions related to the influence of the health system on Canadian CPM rates. Our results suggest that health system factors such as access to immediate breast reconstruction and patient factors such as a family history of breast cancer, both influence Canadian CPM rates. In addition, it should be noted that this study only evaluated immediate CPM and did not identify the number of delayed CPMs that occurred at our institution.

Overall, the immediate CPM rates between 2004 and 2010 at a high-volume Canadian breast cancer center did not demonstrate the same increasing trend documented in the United States. However, in keeping with the United States findings, our analysis showed that Canadian patients who had CPM were generally younger, more often had a breast cancer family history and also had immediate breast reconstruction.

**COMMENTS**

***Background***

Rates of contralateral prophylactic mastectomies (CPM) in women with early stage unilateral invasive breast cancer have been increasing, despite a lack of survival advantage. These rates have mainly been described in literature from the United States. Rates of CPM, and the factors influencing these rates, may be different in the Canadian healthcare system.

***Research frontiers***

CPM is often performed for younger patients and associated with immediate breast reconstruction. With increasing interest in healthcare costs, plus patient satisfaction and outcomes, CPM is an important topic of investigation.

***Innovations and breakthroughs***

CPM rates at a single Canadian institution do not show the same increasing trend as reported in the United States. Similar to United States literature, CPM is associated with immediate reconstruction and patients with a family history.

***Applications***

By identifying findings in contrast to those reported in the United States, further investigation into potential reasons (*i.e*., lack of hospital resources, lack of patient desire, *etc*.) for the difference in CPM rates should be undertaken.

***Terminology***

CPM is the removal of a healthy breast for breast cancer prevention or for cosmetic balancing requirements.

***Peer-review***

The proffered paper is thoughtful, timely, and publishable.

**REFERENCES**

1 **Pesce CE**, Liederbach E, Czechura T, Winchester DJ, Yao K. Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base. *J Am Coll Surg* 2014; **219**: 19-28 [PMID: 24862886 DOI: 10.1016/j.jamcollsurg.2014.03.043]

2 **Tuttle TM**, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. *J Clin Oncol* 2007; **25**: 5203-5209 [PMID: 17954711]

3 **Tuttle TM**, Jarosek S, Habermann EB, Arrington A, Abraham A, Morris TJ, Virnig BA. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. *J Clin Oncol* 2009; **27**: 1362-1367 [PMID: 19224844 DOI: 10.1200/JCO.2008.20.1681]

4 **Bedrosian I**, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. *J Natl Cancer Inst* 2010; **102**: 401-409 [PMID: 20185801 DOI: 10.1093/jnci/djq018]

5 **Brewster AM**, Parker PA. Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. *Oncologist* 2011; **16**: 935-941 [PMID: 21672945 DOI: 10.1634/theoncologist.2011-0022]

6 **Kruper L**, Kauffmann RM, Smith DD, Nelson RA. Survival analysis of contralateral prophylactic mastectomy: a question of selection bias. *Ann Surg Oncol* 2014; **21**: 3448-3456 [PMID: 25047478 DOI: 10.1245/s10434-014-3930-0]

7 **Yao K**, Winchester DJ, Czechura T, Huo D. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002. *Breast Cancer Res Treat* 2013; **142**: 465-476 [PMID: 24218052 DOI: 10.1007/s10549-013-2745-1]

8 **Güth U**, Myrick ME, Viehl CT, Weber WP, Lardi AM, Schmid SM. Increasing rates of contralateral prophylactic mastectomy - a trend made in USA? *Eur J Surg Oncol* 2012; **38**: 296-301 [PMID: 22305274 DOI: 10.1016/j.ejso.2011.12.014]

9 **Neuburger J**, Macneill F, Jeevan R, van der Meulen JH, Cromwell DA. Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics. *BMJ Open* 2013; **3**: pii: e003179 [PMID: 23906951 DOI: 10.1136/bmjopen-2013-003179]

10 **Porter G**, Wagar B, Bryant H, Hewitt M, Wai E, Dabbs K, McFarlane A, Rahal R. Rates of breast cancer surgery in Canada from 2007/08 to 2009/10: retrospective cohort study. *CMAJ Open* 2014; **2**: E102-E108 [PMID: 25077125 DOI: 10.9778/cmajo.20130025]

11 **Arrington AK**, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. *Ann Surg Oncol* 2009; **16**: 2697-2704 [PMID: 19653045 DOI: 10.1245/s10434-009-0641-z]

12 **Soran A**, Kamali Polat A, Johnson R, McGuire KP. Increasing trend of contralateral prophylactic mastectomy: what are the factors behind this phenomenon? *Surgeon* 2014; **12**: 316-322 [PMID: 24685410 DOI: 10.1016/j.surge.2014.02.005]

13 **Stucky CC**, Gray RJ, Wasif N, Dueck AC, Pockaj BA. Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer. *Ann Surg Oncol* 2010; **17** Suppl 3: 330-337 [PMID: 20853055 DOI: 10.1245/s10434-010-1259-x]

14 **Yi M**, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. *Cancer* 2009; **115**: 962-971 [PMID: 19172584 DOI: 10.1002/cncr.24129]

15 **Covelli AM**, Baxter NN, Fitch MI, Wright FC. Increasing mastectomy rates-the effect of environmental factors on the choice for mastectomy: a comparative analysis between Canada and the United States. *Ann Surg Oncol* 2014; **21**: 3173-3184 [PMID: 25081340 DOI: 10.1245/s10434-014-3955-4]

16 **Platt J**, Zhong T, Moineddin R, Booth GL, Easson AM, Fernandes K, Gozdyra P, Baxter NN. Geographic Variation Immediate and Delayed Breast Reconstruction Utilization in Ontario, Canada and Plastic Surgeon Availability: A Population-Based Observational Study. *World J Surg* 2015; **39**: 1909-1921 [PMID: 25896900 DOI: 10.1007/s00268-015-3060-2]

17 **Zhong T**, Fernandes KA, Saskin R, Sutradhar R, Platt J, Beber BA, Novak CB, McCready DR, Hofer SO, Irish JC, Baxter NN. Barriers to immediate breast reconstruction in the Canadian universal health care system. *J Clin Oncol* 2014; **32**: 2133-2141 [PMID: 24888814 DOI: 10.1200/JCO.2013.53.0774]

**P-Reviewer:** Dirier A, Higa GM **S-Editor:** Ji FF **L-Editor: E-Editor:**



**Figure 1 Contralateral prophylactic mastectomy trends.** CPM: Contralateral prophylactic mastectomies.

**Table 1 Patient characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **UM** | **CPM** | ***P* value** |
| ***n* = 759 (94%)** | ***n* = 52 (6%)** |
| **Age (median years, range)** | 52 (28-88) | 49 (29-67) | < 0.001 |
| **Pre-operative diagnosis (%)** |   |   | 0.74 |
| Invasive carcinoma only | 585 (77.1) | 38 (73.1) |   |
| DCIS only | 144 (19.0) | 12 (23.1) |   |
| Invasive + DCIS | 30 (4.0) | 2 (3.8) |   |
| **Previous benign disease (%)** |   |   | 0.26 |
| No | 566 (74.6) | 34 (65.4) |   |
| Yes | 164 (21.6) | 15 (28.8) |   |
| Unknown | 29 (3.8) | 3 (5.8) |   |
| **Pre-op BRCA1/BRCA2 status (%)** |   |   | < 0.001 |
| Negative | 43 (6) | 9 (17) |   |
| Positive | 6 (1) | 11 (21) |   |
| Both unknown | 710 (94) | 32 (62) |   |
| **Family history (%)** |   |   | < 0.001 |
| Positive | 283 (37.3) | 35 (67.3) |   |
| Negative | 440 (58.0) | 13 (25.0) |   |
| Unknown | 36 (4.7) | 4 (7.7) |   |
| **Pre-op systemic therapy (%)** |   |   | 0.23 |
| No | 588 (77) | 36 (69) |   |
| Yes | 171 (23) | 16 (31) |   |
| **Any radiation treatment (%)** |   |   | 0.008 |
| No | 435 (57) | 40 (77) |   |
| Yes | 324 (43) | 12 (23) |   |
| **SLNB (%)** |   |   | 0.76 |
| No | 316 (42) | 20 (38) |   |
| Yes | 443 (58) | 32 (62) |   |
| **ALND (%)** |   |   | < 0.001 |
| No | 387 (51) | 10 (19) |   |
| Yes | 372 (49) | 42 (81) |   |
| **Reconstruction (%)** |   |   | < 0.001 |
| No | 695 (92) | 24 (46) |   |
| Yes | 64 (8) | 28 (54) |   |
| **Local/regional recurrence (%)** |   |   | 0.68 |
| No | 734 (97) | 50 (96) |   |
| Yes | 25 (3) | 2 (4) |   |
| **New contralateral breast cancer (%)** |   |   | 0.05 |
| No  | 746 (98) | 49 (94) |   |
| Yes | 13 (2) | 3 (6) |   |
| **Follow-up (median years, range)** | 2.32 (0.04-7.15) | 2.54 (0.13-6.91) | 0.56 |

UM: Unilateral mastectomy; CPM: Contralateral prophylactic mastectomies; BRCA: Breast cancer; SLNB: Sentinel lymph node biopsy; ALND: Axillary lymph node dissection.

**Table 2 Multivariable analysis**

|  |  |  |  |
| --- | --- | --- | --- |
| **Predictor** | **OR** | **95%CI** | ***P* value** |
| **Age** |   |   | 0.99 |
| < 50 | 1 | 0.52-1.90 |   |
| ≥ 50 | Ref | Ref |   |
| **Family history** |   |   | < 0.001 |
| Yes | 3.56 | 1.83-7.30 |   |
| No | Ref | Ref |   |
| **History of benign disease** |   |   | 0.51 |
| Yes | 1.26 | 0.61-2.49 |   |
| No | Ref | Ref |   |
| **Immediate reconstruction** |   |   | < 0.001 |
| Yes | 10.01 | 5.22-19.32 |   |
| No | Ref | Ref |   |